

# Rui Pedro Marques da Costa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8640426/publications.pdf>

Version: 2024-02-01

8  
papers

120  
citations

1478505

6  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

203  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0268020.	3.2	28
2	Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy. <i>Metabolites</i> , 2021, 11, 699.	2.9	25
3	Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication. <i>Viruses</i> , 2022, 14, 172.	3.3	18
4	SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor. <i>Vaccines</i> , 2021, 9, 706.	4.4	14
5	Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes. <i>Cells</i> , 2020, 9, 1003.	4.1	10
6	SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. <i>Journal of Hepatology</i> , 2019, 70, 603-614.	3.7	9
7	Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 317.	8.6	9
8	Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. <i>Viruses</i> , 2019, 11, 275.	3.3	7